Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 1;16(1):180–188. doi: 10.7150/ijms.27719

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Ivyspring International Publisher

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Combined kidney volumes (A) and weights (B) following 8mo treatment with vehicle or Sulindac. WT (n=21) represents kidneys from either Pkd2^+/WS25 or Pkd2^+/+ mice. (A) Kidney volume in vehicle-treated Pkd2^WS25/- mice (n=9) were significantly elevated when compared to WT kidneys (** p<0.01) and when compared to Sulindac-treated Pkd2^WS25/- mice (n=8) (# p<0.05). Combined kidney volumes of WT, Vehicle, Sulindac: 0.54±0.07, 1.19±0.83, 0.74±0.29. (B) Kidney weights were significantly higher in vehicle-treated Pkd2^WS25/- kidneys when compared to WT kidneys (* p<0.01). Sulindac-treated Pkd2^WS25/- mice had a trend towards lower weights compared to vehicle-treated Pkd2^WS25/- although this did not approach statistical significance. Again there were no statistical differences in kidney weights between WT kidneys and Sulindac-treated Pkd2^WS25/- kidneys.